Current
—
5-Year Average
—
All-Time High
—
All-Time Low
—
P/E Ratio daily chart for Revolution Medicines (RVMD)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
P/E ratio is not shown for periods when TTM earnings were negative.
Historical P/E Ratio for Revolution Medicines (RVMD) from 2019 to 2025
| 2025 | $15.14B | −$1.13B | — | — | |
| 2024 | $7.34B | −$600.09M | — | — | |
| 2023 | $4.05B | −$436.37M | — | — | |
| 2022 | $2.12B | −$248.71M | — | — | |
| 2021 | $1.86B | −$187.09M | — | — | |
| 2020 | $2.63B | −$108.16M | — | — | |
| 2019 | $1.05B | −$47.66M | — | — |
- 2025—
- 2024—
- 2023—
- 2022—
- 2021—
- 2020—
- 2019—
About P/E Ratio at Revolution Medicines (RVMD)
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Revolution Medicines (RVMD), ranked by P/E ratio.
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric